



**TITLE: Quetiapine Use in Correctional Facilities: Clinical Evidence, Abuse Potential, and Guidelines**

**DATE:** 8 July 2010

**RESEARCH QUESTIONS:**

1. What is the clinical evidence for the use of quetiapine for patients with anxiety and/or sleep issues in correctional facilities?
2. What is the evidence for the abuse potential of quetiapine within correctional facilities?
3. What are the evidence-based guidelines for the use of quetiapine for patients with anxiety and/or sleep issues in correctional facilities?

**METHODS:**

A limited literature search was conducted on key health technology assessment resources, including PubMed, the Cochrane Library (Issue 6, 2010), University of York Centre for Reviews and Dissemination (CRD) databases, ECRI (Health Devices Gold), EuroScan, international health technology agencies, and a focused Internet search. The search was limited to human, English language articles published between January 1, 2005 and July 4, 2010. No filters were applied to limit the retrieval by study type. Internet links were provided, where available.

**RESULTS:**

HTIS reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials, non-randomized studies, and evidence-based guidelines.

No relevant health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, or non-randomized studies were identified regarding the clinical evidence for the use of quetiapine for patients with anxiety and/or sleep issues in correctional facilities or the

Disclaimer: The Health Technology Inquiry Service (HTIS) is an information service for those involved in planning and providing health care in Canada. HTIS responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. HTIS responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report.

Copyright: This report contains CADTH copyright material and may contain material in which a third party owns copyright. **This report may be used for the purposes of research or private study only.** It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner.

Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners' own terms and conditions.

evidence for the abuse potential of quetiapine in correctional facilities. No evidence-based guidelines for the use of quetiapine for patients with anxiety and/or sleep issues in correctional facilities were identified. Additional articles of potential interest can be found in the appendix.

**OVERALL SUMMARY OF FINDINGS:**

No relevant studies were identified, therefore, no summary pertaining to the clinical evidence or evidence-based guidelines for the use of quetiapine for patients with anxiety and/or sleep issues in correctional facilities can be presented. Narrative articles discussing the abuse potential of quetiapine within correctional facilities can be found in the appendix.

**REFERENCES SUMMARIZED:**

**Health technology assessments**

No literature identified

**Systematic reviews and meta-analyses**

No literature identified

**Randomized controlled trials**

No literature identified

**Non-randomized studies**

No literature identified

**Guidelines and recommendations**

No literature identified

**PREPARED BY:**

Health Technology Inquiry Service

Email: [htis@cadth.ca](mailto:htis@cadth.ca)

Tel: 1-866-898-8439

**APPENDIX – FURTHER INFORMATION:**

**Studies specific to use or misuse of quetiapine in correctional facilities**

*Review articles*

1. Hanley MJ, Kenna GA. Quetiapine: treatment for substance abuse and drug of abuse. *Am J Health Syst Pharm.* 2008 Apr 1;65(7):611-8. [PubMed: PM18359967](#)
2. Keltner NL, Vance DE. Biological perspectives incarcerated care and quetiapine abuse. *Perspect Psychiatr Care.* 2008 Jul;44(3):202-6. [PubMed: PM18577126](#)

*Additional references*

3. Sansone RA, Sansone LA. Is seroquel developing an illicit reputation for misuse/abuse? *Psychiatry (Edgmont)* [Internet]. 2010 Jan [cited 2010 Jul 7];7(1):13-6. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2848462> [PubMed: PM20386631](#)
4. Laird B, Narayan P. Formulary controls: abuse of psychotropics, and dispensary costs in the incarceration environment. Presented at: Making an impact. 34th Annual Forensic Mental Health Association of California conference [Internet]; 2009 Mar 18-20. San Francisco (CA): FMHAC; 2009 [cited 2010 Jul 3]. Available from: <http://www.fmhac.net/Assets/Documents/2009/Presentations/Laird%20Formulary%20Controls.pdf>.
5. Idaho Drug Utilization Review Program. Misuse of atypical antipsychotics [Internet]. Pocatello (ID): ISU College of Pharmacy; 2008 Apr [cited 2010 Jul 3]. Available from: [http://idahodur.isu.edu/leaflets/2008/Atypical\\_Antipsychotic.pdf](http://idahodur.isu.edu/leaflets/2008/Atypical_Antipsychotic.pdf).  
*Note: see Abuse and Diversion of Quetiapine, page 2*
6. Smith D, Bugaoan R, Renner J. Are second generation antipsychotics abusable or addictive? A focus on quetiapine [NR1-002]. Abstract presented at: American Psychiatric Association 161st annual meeting [Internet]; 2008 May 3-8; Washington, DC; 2008. [cited 2010 Jul 3]. Available from: <http://www.psych.org/am2008newresearch>.
7. Hussain MZ, Waheed W, Hussain S. Intravenous quetiapine abuse. *Am J Psychiatry.* 2005 Sep;162(9):1755-6. [PubMed: PM16135642](#)

**Studies not specific to use in correctional facilities**

*Randomized controlled trials*

8. Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggen I, Liu S, et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. *Int J Neuropsychopharmacol.* 2010 Apr;13(3):305-20. [PubMed: PM19691907](#)

9. Tassniyom K, Paholpak S, Tassniyom S, Kiewyoo J. Quetiapine for primary insomnia: a double blind, randomized controlled trial. *J Med Assoc Thai*. 2010 Jun;93(6):729-34. [PubMed: PM20572379](#)

*Non-randomized studies*

10. Katzman MA, Vermani M, Jacobs L, Marcus M, Kong B, Lessard S, et al. Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. *J Anxiety Disord*. 2008 Dec;22(8):1480-6. [PubMed: PM18455360](#)

*Review articles*

11. Wine JN, Sanda C, Caballero J. Effects of quetiapine on sleep in nonpsychiatric and psychiatric conditions. *Ann Pharmacother*. 2009 Apr;43(4):707-13. [PubMed: PM19299326](#)